Publications dans lesquelles il/elle collabore avec Salvador Resino García (17)

2024

  1. Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV

    The Journal of infectious diseases, Vol. 230, Núm. 2, pp. 421-425

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2021

  1. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  2. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

2020

  1. Brief Report: CYP27B1 rs10877012 T Allele Was Linked to Non-AIDS Progression in ART-Naïve HIV-Infected Patients: A Retrospective Study

    Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 5, pp. 659-664

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

  2. Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

    Journal of Translational Medicine, Vol. 16, Núm. 1

2016

  1. Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit

    BMC Infectious Diseases, Vol. 16, Núm. 1

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2014

  1. Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): Significant role of chronic hepatitis C and severe sepsis

    Critical Care, Vol. 18, Núm. 4

2013

  1. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

    AIDS, Vol. 27, Núm. 8, pp. 1231-1238

2011

  1. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

  2. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy

    Journal of Infection, Vol. 63, Núm. 5, pp. 382-390

2010

  1. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

    Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886

  2. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV

    Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216

2009

  1. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401